Triptorelin: what the research shows
- By Reed Calder
- Last reviewed Nov 16, 2026
- 42 studies and official documents checked
In short
Triptorelin is a lab-made peptide of 10 amino acids and a GnRH agonist: a copy of the brain hormone GnRH (gonadorelin) with one amino acid changed, D-tryptophan in place of glycine at position 6. In the FDA label’s lab tests it was 100 times more active than natural GnRH at releasing LH from rat pituitary cells. Given as a long-acting depot injection, it first raises LH, FSH and testosterone or estradiol for a few days, then switches them off within 2 to 4 weeks. That is the opposite of the pulse use of gonadorelin.
The FDA has approved it for two uses: advanced prostate cancer (Trelstar, first approved in 2000) and central precocious puberty in children 2 and older (Triptodur, 2017). In the label trials, 91.2% to 97.7% of men reached castration-level testosterone by day 29, and in 44 children at least 93% reached prepubertal LH levels at every check. Those trials measured hormone levels, not survival or final height.
Other uses have weaker evidence. In the U.K., triptorelin products are also approved for endometriosis, fibroids before surgery, premenopausal breast cancer and, as Salvacyl, severe sexual deviations. A pooled analysis of five trials found that GnRH agonists during chemotherapy cut early menopause in women with breast cancer from 30.9% to 14.1%, but a lymphoma trial found no benefit. For men, triptorelin does not raise testosterone: it lowers it, and the label warns of tumor flare, heart attack and stroke, diabetes-type changes and fetal harm. The 2026 WADA list prohibits GnRH agonists, triptorelin among them, at all times in male athletes.
EvidenceCellAnimalHumanapproved for prostate cancer and early puberty; other uses studied in trials of varying size
You’ll often read that triptorelin is a peptide that restarts testosterone, protects fertility on testosterone therapy, helps with weight loss or is a safe, simple way to “reset” hormones. This page covers what triptorelin is, what the approved and other uses are based on, the usual claims checked, what the studies used, side effects, where it stands with the FDA and in sport, and what’s still unknown.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| Triptorelin | A synthetic decapeptide agonist analog of GnRH, with the formula C64H82N18O13 and a weight of 1,311.4 g/mol (PubChem CID 25074470; Trelstar label) | Yes: injections, for decades |
| Triptorelin pamoate (embonate) | The salt in the FDA-approved depots Trelstar and Triptodur, slow-release injections given every 4, 12 or 24 weeks (Trelstar label; Triptodur label) | Yes: the approved products |
| Triptorelin acetate | Another salt, used in 1-month injections in some trials; one registered trial compares a 3-month pamoate injection with a 1-month acetate one (NCT06487143) | Yes, in trials |
| Trelstar, Triptodur; Decapeptyl, Gonapeptyl, Salvacyl | Brand names: Trelstar and Triptodur in the U.S.; Decapeptyl, Gonapeptyl and Salvacyl are U.K. products (Decapeptyl SR 3 mg; Gonapeptyl Depot; Salvacyl) | Yes: the approved products |
| GnRH, LHRH, gonadorelin | The natural hormone that triptorelin copies. See gonadorelin | Covered on its own page |
| Leuprolide, goserelin, buserelin, nafarelin, histrelin, deslorelin | Other GnRH agonists. The WADA list names them next to triptorelin (WADA, 2026) | Not covered here |
| Kisspeptin | A different peptide one step upstream that makes the brain release GnRH. See kisspeptin | Covered on its own page |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The number below is for triptorelin itself; each salt and brand has its own entries.
| Form | CAS number | Registry record |
|---|---|---|
| Triptorelin | 57773-63-4 | PubChem |
What triptorelin is
Triptorelin is a synthetic decapeptide agonist analog of GnRH. Its chemical name matches the body’s GnRH except at position 6, where triptorelin has D-tryptophan and the natural hormone has glycine (Trelstar label; UniProt). In lab tests it was 100 times more active than natural GnRH at releasing LH from rat pituitary cells and 20 times more active at displacing GnRH from its receptor (Trelstar label).
GnRH tells the pituitary to release LH and FSH, which tell the testes or ovaries to make sex hormones; see gonadorelin. The pattern of exposure decides the effect: in four men, pulses of gonadorelin raised LH and FSH while the same total dose as a steady infusion did not raise active LH or FSH (Matsumoto et al., 1991). A triptorelin depot gives a steady signal on purpose.
After the first injection there is a brief surge in LH, FSH, testosterone and estradiol. In men, testosterone peaks on day 2 to 4, depending on the product, and falls to low levels by weeks 3 to 4; the sustained drop in LH and FSH and the fall of testosterone to the level seen after surgical castration usually follow within 2 to 4 weeks. The label says these effects are usually reversible after treatment stops (Trelstar label).
What has been studied
Advanced prostate cancer (FDA-approved)
| Study | Who | What was used | What it found |
|---|---|---|---|
| Trelstar label, 3.75 mg | 277 men with advanced prostate cancer; randomized, active control (140 on triptorelin) | Triptorelin 3.75 mg or another approved GnRH agonist every month for 9 months | Castration-level testosterone (50 ng/dL or less) by day 29 in 125 of 137 men (91.2%), and 97.7% by day 57. Maintained from day 57 to 253 in 96.2% |
| Trelstar label, 11.25 mg | 346 men with advanced prostate cancer; randomized, active control | 11.25 mg every 12 weeks (174 men) or 3.75 mg every 28 days (172 men) | Castration by day 29 in 167 of 171 men on 11.25 mg (97.7%); maintained from day 57 to 253 in 94.4% |
| Trelstar label, 22.5 mg | 120 men with advanced prostate cancer; one group, no comparison | 22.5 mg every 24 weeks, two doses | Castration by day 29 in 117 of 120 men (97.5%); maintained from day 57 to 337 in 93.3% |
| Teillac et al., 2004 | 131 men with advanced prostate cancer; randomized | A 3-month formulation (63 men) against a 28-day formulation given three times (68 men) | Castration (testosterone 0.5 ng/mL or less) in 98% and 96%; median time to castration about 18.8 and 18.5 days; PSA fell 91.0% and 91.7%. The authors call the two formulations pharmacologically equivalent |
| Østergren et al., 2019 | 58 hormone-naive men with advanced prostate cancer; randomized | Triptorelin 22.5 mg every 24 weeks or surgical removal of the testicles, followed 48 weeks | Androgen deprivation increased fat mass, abdominal fat, cholesterol and insulin resistance and lowered lean body mass within 12 to 24 weeks. Fat accumulation was greater after surgery than with the injection |
The label trials measured testosterone, not survival or tumor outcomes. A systematic review of 16 head-to-head trials of the GnRH agonists goserelin, triptorelin and leuprorelin found no major differences in lowering testosterone or PSA, none was powered for survival, and the authors say there is not enough evidence to show the drugs are equivalent (Bolton et al., 2018).
EvidenceCellAnimalHumanapproved; label trials measured hormone levels, not survival
Central precocious puberty in children (FDA-approved)
| Study | Who | What was used | What it found |
|---|---|---|---|
| Triptodur label | 44 children aged 2 to 9 (39 girls, 5 boys), never treated before; one group, no comparison | Triptodur 22.5 mg every 24 weeks, two doses, followed 12 months | At least 93% had LH suppressed to prepubertal levels at every check (41 of 44, 93%, at month 6, the main goal). At least 79% of girls reached prepubertal estradiol and at least 80% of boys prepubertal testosterone. 95% showed no increase in the bone age to age ratio and 89% had stable sexual maturation at month 12 |
| Durand et al., 2017 | Meta-analysis of all studies of the 11.25 mg 3-month injection: 153 children (13 boys, 140 girls) | Triptorelin 11.25 mg every 3 months | Peak LH after a GnRH test was suppressed in 87.6% at 3 months and 92.8% at 6 months; estradiol suppressed in 97.1% of children at 3 months |
| Yu et al., 2024 | 66 Chinese children (93.9% girls), phase 3, one group | Triptorelin pamoate 22.5 mg at day 1 and month 6 | All children had LH suppression at month 6, maintained at month 12 in 98.5%. Growth and signs of puberty slowed. No child stopped because of side effects |
| Carel et al., 1999 | 58 girls and 8 boys treated for early puberty; compared with their predicted height and a historical untreated group | Triptorelin slow-release injections for years | Final height was close to genetic target. In girls it was 4.8 cm above predicted height and 8.3 cm above the untreated group; in boys it matched predicted height. The authors say continuing past age 11 in girls does not improve and could lower final height, and call for a controlled trial |
Reviews of GnRH agonists as a group, not triptorelin alone, found that for girls with idiopathic early puberty adult height was 2.7 cm greater with treatment in 21 comparative observational studies of 1,835 girls (Firwana et al., 2026), and 4.83 cm greater in 4 comparative studies, with the evidence graded very low to moderate and little data on boys (Luo et al., 2021).
EvidenceCellAnimalHumanapproved; a single-arm label trial; height benefit comes from observational comparisons
Endometriosis and fibroids (U.K. approvals, not U.S.)
| Study | Who | What was used | What it found |
|---|---|---|---|
| Cirkel et al., 1995 | 55 women with endometriosis; randomized | Triptorelin depot (30 women) or danazol (25) for 24 weeks | Both cut endometriotic implants (58% and 51%) and ended painful periods; pain with intercourse and pelvic pain fell by at least half. Estradiol suppression was greater with triptorelin, whose urinary calcium rose, and side effects followed the low estrogen |
| Cosson et al., 2002 | 120 women analyzed after surgery for endometriosis; randomized, open | Dienogest 1 mg a day or Decapeptyl 3.75 mg every 4 weeks, for 16 weeks | No significant difference in the endometriosis score. Adverse events were reported by 87.7% on dienogest and 85.1% on triptorelin |
| Donnez et al., 2004 | 146 women with endometriosis; randomized | One 3-month injection (72 women) or 28-day injections for 3 months (74) | Castration-level estradiol on day 84 in 97% and 94%; the 3-month form kept it longer |
For GnRH agonists as a group, a Cochrane review found they may slightly reduce overall endometriosis pain compared with placebo or progestogens, with uncertain results against danazol, a slight loss of bone density and more adverse effects, all rated very low to low certainty (Veth et al., 2023). Before fibroid surgery, 36 of 41 randomized trials (3,982 women) tested GnRH agonists: they may reduce uterus and fibroid size and probably raise hemoglobin, with more adverse events such as hot flushes (Puscasiu et al., 2025).
EvidenceCellAnimalHumansmall randomized trials; class reviews of low certainty
Breast cancer and protecting the ovaries during chemotherapy
| Study | Who | What was used | What it found |
|---|---|---|---|
| Perrone et al., 2019 (HOBOE) | 1,065 premenopausal women with hormone receptor-positive early breast cancer, all given triptorelin to suppress the ovaries | Tamoxifen, letrozole, or letrozole plus zoledronic acid for 5 years | Five-year disease-free rates were 85.4%, 93.2% and 93.3% (overall p = 0.008). Letrozole against tamoxifen: hazard ratio 0.72 (0.48 to 1.07, p = 0.06). No survival difference after 36 deaths |
| Pagani et al., 2014 (TEXT and SOFT) | 4,690 premenopausal women with hormone receptor-positive early breast cancer, two phase 3 trials | Exemestane or tamoxifen with ovarian suppression by triptorelin, oophorectomy or irradiation, for 5 years | Five-year disease-free survival 91.1% with exemestane and 87.3% with tamoxifen (hazard ratio 0.66). Overall survival did not differ. Grade 3 or 4 events 30.6% and 29.4% |
| Lambertini et al., 2015 (PROMISE-GIM6) | 281 premenopausal women having chemotherapy for breast cancer; randomized, open | Chemotherapy alone or with triptorelin | Menstruation resumed by 5 years in 72.6% with triptorelin and 64.0% without (hazard ratio 1.28, p = 0.07; age-adjusted 1.48, p = 0.006). Pregnancies: 8 and 3. Disease-free survival 80.5% and 83.7% (p = 0.52) |
| Lambertini et al., 2022 | The same trial after 12.4 years | Chemotherapy alone or with triptorelin | Disease-free survival 65.7% and 69.2% (hazard ratio 1.16, 0.76 to 1.77); overall survival 81.2% and 81.3%. Pregnancies after treatment 9 and 4 |
| Lambertini et al., 2018 | Pooled data on 873 women from 5 trials of GnRH agonists during breast cancer chemotherapy | Chemotherapy alone or with a GnRH agonist | Premature ovarian insufficiency in 14.1% and 30.9% (adjusted odds ratio 0.38, 0.26 to 0.57). Pregnancy after treatment in 10.3% and 5.5%. No significant difference in disease-free survival or overall survival |
| Demeestere et al., 2016 | 129 women with lymphoma; randomized | Triptorelin plus norethisterone or norethisterone alone during chemotherapy | Premature ovarian failure was unrelated to triptorelin (odds ratio 0.702, p = 0.651). Pregnancy in 53% and 43% (p = 0.467). The authors say it should not be standard for fertility protection in lymphoma |
EvidenceCellAnimalHumanlarge randomized trials in breast cancer; a null result in lymphoma
In vitro fertilization (IVF)
Reviews of GnRH agonists as a group, with triptorelin one of the drugs used, found: in a Cochrane review of 40 trials of agonist protocols, little or no difference in live birth between long and short protocols, with the long protocol possibly improving clinical pregnancy, and low to very low certainty (Siristatidis et al., 2025). Using an agonist instead of hCG to trigger egg maturation in fresh antagonist cycles prevented ovarian hyperstimulation to the detriment of live birth rate, and made no difference to live birth in donor-recipient cycles (Youssef et al., 2014).
EvidenceCellAnimalHumanclass reviews; triptorelin is not separated from other GnRH agonists
Severe sexual deviations (paraphilia)
| Study | Who | What was used | What it found |
|---|---|---|---|
| Rösler et al., 1998 | 30 men with severe, long-standing paraphilia (25 with pedophilia); uncontrolled, no comparison group | Triptorelin 3.75 mg a month with supportive psychotherapy for 8 to 42 months | All 30 men had fewer deviant fantasies (48 a week to zero) and abnormal incidents (5 a month to zero), and the effect lasted in all 24 who continued for at least a year. Testosterone fell from 545 to 23 ng/dL after 42 months. Side effects: erectile failure, hot flashes and lower bone density in some men |
| Thibaut et al., 1993 | 6 men with severe paraphilia; case series | Triptorelin 3.75 mg a month | Five ended deviant behavior; one stopped treatment after a year and relapsed within 10 weeks |
We found no controlled trial: a planned double-blind trial in German forensic hospitals was rejected by the regulator, and an ethics committee held that research with patients detained in forensic hospitals was basically not possible (planning ran 2009 to 2015) (Briken et al., 2017). In the U.K., Salvacyl is approved for adult men with severe sexual deviations, to be started and controlled by a psychiatrist and given with psychotherapy (Salvacyl summary).
EvidenceCellAnimalHumanuncontrolled studies; no randomized trial
Puberty suppression in adolescents with gender dysphoria
Two systematic reviews of GnRH agonists as a group, not triptorelin alone, found consistent evidence that they suppress puberty. Height increased but not in line with expected growth, and bone density fell during treatment. Evidence on gender dysphoria, psychological health, heart and metabolic risk, thinking and fertility was limited or inconsistent, and the authors could draw no conclusions on mental health outcomes; another review graded the certainty of the evidence very low (Taylor et al., 2024; Miroshnychenko et al., 2025). This use is not on the FDA labels, which cover prostate cancer and early puberty.
EvidenceCellAnimalHumancohort and before-after studies; very low certainty
Obsessive-compulsive disorder
A systematic review of anti-androgens found one randomized trial (of flutamide) and four non-randomized trials. Three of the four non-randomized trials, using finasteride, cyproterone acetate or triptorelin, reported fewer OCD symptoms, and the authors rate the evidence low quality and insufficient (Nomani et al., 2020).
EvidenceCellAnimalHumansmall non-randomized trials; low-quality evidence
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| Triptorelin raises testosterone | Contradicted | It raises it for a few days, then lowers it to castration level: 91.2% to 97.7% of men were at 50 ng/dL or less by day 29, and in 30 men with paraphilia mean testosterone fell from 545 to 23 ng/dL by 42 months (Trelstar label; Rösler et al., 1998) |
| It restarts your testosterone after a steroid cycle | Untested | We found no study in men after steroids. Every depot study we read lowered testosterone, and the drug’s approved use depends on that (Trelstar label) |
| It protects testicular function and fertility on testosterone therapy | Contradicted | The U.S. label lists testicular atrophy among the common reactions to the 22.5 mg depot, MedlinePlus says it may impair fertility in men, and Mayo notes some men became infertile. We found no trial in men on testosterone (Trelstar label; MedlinePlus; Mayo Clinic) |
| It helps you lose weight or fat | Contradicted | In 58 men, androgen deprivation with triptorelin or surgery increased fat mass, abdominal fat, cholesterol and insulin resistance and lowered lean mass within 12 to 24 weeks. We found no weight-loss trial (Østergren et al., 2019) |
| It builds muscle | Contradicted | Lean body mass fell in the prostate study, we found no study of athletic performance, and the WADA list prohibits GnRH agonists in male athletes (Østergren et al., 2019; WADA, 2026) |
| It is an effective treatment for advanced prostate cancer | Supported | It is FDA-approved for it, and the label trials showed castration-level testosterone in 91.2% to 97.7% of men by day 29. Those trials measured hormone levels, and head-to-head trials of GnRH agonists were small and not powered for survival (Trelstar label; Bolton et al., 2018) |
| It treats central precocious puberty | Supported | It is FDA-approved for it. In 44 children at least 93% reached prepubertal LH at every check, and a meta-analysis of 153 children found LH suppressed in 92.8% at 6 months (Triptodur label; Durand et al., 2017) |
| It makes children with early puberty taller | Mixed | Observational comparisons in girls found adult height 2.7 to 4.8 cm greater with GnRH agonists, rated very low to moderate certainty, with little data in boys and no randomized trial of final height (Firwana et al., 2026; Luo et al., 2021) |
| It relieves endometriosis pain | Mixed | It was as effective as danazol and dienogest in small trials, but a 2023 Cochrane review rates the evidence very low to low, with a slight loss of bone density (Cirkel et al., 1995; Cosson et al., 2002; Veth et al., 2023) |
| It protects the ovaries and fertility during chemotherapy | Mixed | In breast cancer, GnRH agonists cut early menopause from 30.9% to 14.1% in a pooled analysis, and more women who had triptorelin resumed periods, but in 129 women with lymphoma it did not help (Lambertini et al., 2018; Lambertini et al., 2015; Demeestere et al., 2016) |
| It improves IVF success | Mixed | GnRH agonist protocols made little or no difference to live birth in a Cochrane review, and an agonist trigger instead of hCG lowered live birth in fresh cycles while preventing ovarian hyperstimulation. The reviews do not separate triptorelin (Siristatidis et al., 2025; Youssef et al., 2014) |
| It treats paraphilia | Mixed | Uncontrolled studies of 30 and 6 men reported that deviant behavior stopped, a controlled trial was never run, and a U.K. product is approved for severe cases with psychotherapy (Rösler et al., 1998; Thibaut et al., 1993; Briken et al., 2017; Salvacyl) |
| It treats obsessive-compulsive disorder | Mixed | Three of four small non-randomized anti-androgen trials, including one of triptorelin, reported fewer symptoms; the evidence is low quality (Nomani et al., 2020) |
| It suppresses puberty in adolescents with gender dysphoria | Supported | Systematic reviews found consistent evidence of puberty suppression for GnRH agonists as a group, with reduced bone density during treatment and limited evidence on other outcomes (Taylor et al., 2024; Miroshnychenko et al., 2025) |
| It has few side effects | Contradicted | In the 3.75 mg label trial 82 of 140 men (58.6%) had hot flushes, and the label warns of tumor flare, metabolic syndrome, heart attack, stroke, sudden cardiac death, convulsions, severe skin reactions and QT prolongation (Trelstar label) |
| Triptorelin is a peptide | Supported | Yes. The label calls it a synthetic decapeptide, a chain of 10 amino acids (Trelstar label) |
| Triptorelin is FDA-approved for endometriosis, fibroids or IVF | Contradicted | No. The U.S. labels cover advanced prostate cancer (Trelstar) and central precocious puberty (Triptodur). Those other uses are on U.K. product summaries (Trelstar label; Triptodur label; Decapeptyl SR 3 mg) |
| Triptorelin is banned in sport | Supported | For male athletes, yes. The 2026 WADA list names GnRH agonist analogues, triptorelin among them, prohibited at all times (WADA, 2026) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
What the studies and labels used
| Source | What was tested | Amount and route |
|---|---|---|
| Trelstar label | Advanced prostate cancer | 3.75 mg every 4 weeks, 11.25 mg every 12 weeks or 22.5 mg every 24 weeks, into a muscle |
| Triptodur label | Central precocious puberty in children | 22.5 mg every 24 weeks, into a muscle |
| Østergren et al., 2019 | Metabolic effects in prostate cancer | 22.5 mg every 24 weeks for 48 weeks |
| Cosson et al., 2002 | Endometriosis after surgery | Decapeptyl 3.75 mg every 4 weeks for 16 weeks |
| Rösler et al., 1998 | Paraphilia | 3.75 mg a month for 8 to 42 months, with psychotherapy |
Every amount above is a depot injection given by a nurse or doctor into a muscle, on a fixed schedule (Mayo Clinic). The labels are for specific products and conditions, and nothing here is a dosing recommendation. We don’t repeat schedules from seller pages.
Side effects and safety
- In the prostate cancer label trials. The most common reactions (5% or more) were hot flushes, skeletal pain, impotence and headache on 3.75 mg; hot flushes, skeletal pain, headache, leg swelling and leg pain on 11.25 mg; and hot flushes, erectile dysfunction and testicular atrophy on 22.5 mg. On 3.75 mg, hot flushes occurred in 82 of 140 men (58.6%) (Trelstar label).
- Warnings on the Trelstar label. Allergic reactions including anaphylaxis, tumor flare that can worsen prostate cancer and cause spinal cord compression or urinary blockage, metabolic changes such as high blood sugar, diabetes and fatty liver, heart attack, sudden cardiac death and stroke, convulsions, severe skin reactions (added August 2025), and QT prolongation. It can cause fetal harm (Trelstar label).
- In children. The Triptodur label warns of a rise in puberty signs in the first 2 to 4 weeks (including vaginal bleeding), psychiatric events such as crying, irritability and aggression, convulsions, severe skin reactions and pseudotumor cerebri, a rise in pressure in the head. The most common reactions were injection-site reactions, menstrual bleeding, hot flush, headache, cough and infections (Triptodur label).
- Metabolic changes. In 58 men, fat mass, abdominal fat, cholesterol and insulin resistance rose within 12 to 24 weeks (Østergren et al., 2019).
- Bone and fertility. Bone density fell in some men on triptorelin for paraphilia, urinary calcium rose in women on triptorelin for endometriosis, and puberty-suppression reviews report reduced bone density; MedlinePlus and Mayo say it may impair fertility in men (Rösler et al., 1998; Cirkel et al., 1995; Taylor et al., 2024; MedlinePlus; Mayo Clinic).
- Pregnancy. Triptodur is contraindicated in pregnancy, and the Trelstar label says it can cause fetal harm because the hormone changes raise the risk of pregnancy loss (Triptodur label; Trelstar label).
- Product quality. We found no analysis of triptorelin sold online as a research chemical.
- Not known. Long-term safety in children and adolescents beyond the trials above, and effects in men on testosterone therapy. Side effects people report online aren’t covered here; they come from users, not studies.
Legal and approval status
- FDA-approved, by prescription. Drugs@FDA lists four applications: Trelstar 3.75 mg (NDA020715, approved June 15, 2000), 11.25 mg (NDA021288, June 29, 2001) and 22.5 mg (NDA022437, March 10, 2010) for advanced prostate cancer, and Triptodur 22.5 mg (NDA208956, June 29, 2017) for central precocious puberty in children 2 and older. The current labels are effective June 30, 2026 (Trelstar) and September 14, 2025 (Triptodur) (NDA020715; NDA021288; NDA022437; NDA208956; Trelstar label; Triptodur label).
- Listings. The FDA’s drug-listing data show the Trelstar and Triptodur kits and 10 further listings that are bulk powder or “drug for further processing” (openFDA NDC).
- Compounding. Triptorelin isn’t named in the FDA’s list of bulk substances nominated for compounding under section 503A, updated May 14, 2026, or on its page of bulk substances that may present significant safety risks, current as of April 22, 2026 (FDA document; FDA page). We did not research whether pharmacies may lawfully compound it.
- Not in the HHS policy. The October 2026 temporary policy covers six other peptides (Reuters, 2026).
- Outside the U.S. We checked only the U.K. summaries of product characteristics. Decapeptyl SR 3 mg lists prostate cancer, endometriosis, uterine fibroids before surgery and, with tamoxifen or an aromatase inhibitor, early breast cancer in women confirmed premenopausal after chemotherapy; Gonapeptyl Depot lists prostate cancer, fibroids, endometriosis and central precocious puberty; Salvacyl lists severe sexual deviations in adult men (Decapeptyl SR 3 mg; Gonapeptyl Depot; Salvacyl).
- Sport. The World Anti-Doping Agency’s 2026 list, section S2.2.1, names GnRH, gonadorelin and its agonist analogues, including triptorelin, among testosterone-stimulating peptides in males, prohibited at all times (WADA, 2026).
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and from the FDA:
- Which direction it pushes. A triptorelin depot lowers testosterone and estrogen. A page that sells it as a way to raise testosterone or restart it is describing the opposite of what the label shows.
- Whose evidence it is. The pulse results for gonadorelin and the fertility results for hCG don’t carry over to a steady GnRH agonist.
- “FDA-approved.” Ask for what: advanced prostate cancer and central precocious puberty in children, as a prescription depot given by a clinician.
- Hormone level versus outcome. The label trials show testosterone or LH suppression. That is not the same as survival, height or symptom relief.
- Class evidence. Many IVF, puberty and chemotherapy reviews cover GnRH agonists as a group. Check whether triptorelin itself was studied.
- Competition. For men, the 2026 WADA list prohibits it at all times.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.
Trials under way
Twenty-two trials that test triptorelin itself are open or about to open, in IVF, breast cancer, early puberty, endometriosis and prostate cancer: see the list, with sponsor, phase, size and registry links.
Already under way: 1 active, not recruiting and 1 finished with no results posted.
What’s still unknown
- Whether triptorelin does anything useful for men on testosterone therapy or after steroids; we found no trial, and its depot dosing lowers testosterone.
- Final height after treatment of early puberty in randomized trials, and results in boys; the evidence is observational.
- Which GnRH agonist is best in prostate cancer, IVF or early puberty; head-to-head trials are few and small.
- The effect of puberty suppression on mental health in adolescents with gender dysphoria; the reviews find limited or inconsistent evidence.
- Whether any controlled trial will test triptorelin for severe paraphilia; the one proposed in Germany was never run.
- What is in triptorelin sold online; we found no analysis.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Triptorelin. We recheck every month. Last checked Nov 16, 2026.
We found no retracted, withdrawn or flagged studies that mention Triptorelin.
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Matsumoto et al., 1991 | Int J Androl | No retraction or concern |
| Cirkel et al., 1995 | Eur J Obstet Gynecol Reprod Biol | No retraction or concern |
| Thibaut et al., 1993 | Acta Psychiatr Scand | No retraction or concern |
| Rösler and Witztum, 1998 | N Engl J Med | No retraction or concern |
| Carel et al., 1999 | J Clin Endocrinol Metab | No retraction or concern |
| Cosson et al., 2002 | Fertil Steril | No retraction or concern |
| Donnez et al., 2004 | Fertil Steril | No retraction or concern |
| Teillac et al., 2004 | Horm Res | No retraction or concern |
| Pagani et al., 2014 | N Engl J Med | No retraction or concern |
| Youssef et al., 2014 | Cochrane Database Syst Rev | No retraction or concern |
| Lambertini et al., 2015 | JAMA | No retraction or concern |
| Demeestere et al., 2016 | J Clin Oncol | No retraction or concern |
| Briken et al., 2017 | Nervenarzt | No retraction or concern |
| Durand et al., 2017 | Horm Res Paediatr | No retraction or concern |
| Bolton and Lynch, 2018 | BJU Int | No retraction or concern |
| Lambertini et al., 2018 | J Clin Oncol | No retraction or concern |
| Østergren et al., 2019 | BJU Int | No retraction or concern |
| Perrone et al., 2019 | Eur J Cancer | No retraction or concern |
| Nomani et al., 2020 | Curr Med Chem | No retraction or concern |
| Luo et al., 2021 | Clin Endocrinol (Oxf) | No retraction or concern |
| Lambertini et al., 2022 | J Natl Cancer Inst | No retraction or concern |
| Veth et al., 2023 | Cochrane Database Syst Rev | No retraction or concern |
| Taylor et al., 2024 | Arch Dis Child | No retraction or concern |
| Yu et al., 2024 | Adv Ther | No retraction or concern |
| Siristatidis et al., 2025 | Cochrane Database Syst Rev | No retraction or concern |
| Miroshnychenko et al., 2025 | Arch Dis Child | No retraction or concern |
| Puscasiu et al., 2025 | Cochrane Database Syst Rev | No retraction or concern |
| Firwana et al., 2026 | J Clin Endocrinol Metab | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is triptorelin?
Triptorelin is a lab-made GnRH agonist, a peptide of 10 amino acids that copies the brain hormone GnRH with one amino acid changed. It is a prescription depot injection (Trelstar label; UniProt).
Is triptorelin a peptide?
Yes. The label calls it a synthetic decapeptide, with a molecular weight of 1,311.4 g/mol (Trelstar label; PubChem CID 25074470).
What is triptorelin used for?
In the U.S., advanced prostate cancer (Trelstar) and central precocious puberty in children 2 and older (Triptodur). U.K. products also list endometriosis, fibroids before surgery, premenopausal breast cancer and severe sexual deviations (Trelstar label; Triptodur label; Decapeptyl SR 3 mg; Salvacyl).
How does triptorelin work?
It stimulates the pituitary for a few days, then, with steady dosing, the pituitary stops responding, LH and FSH fall, and testosterone or estradiol drops to very low levels within 2 to 4 weeks. The effects are usually reversible after treatment stops (Trelstar label).
Does triptorelin lower testosterone?
Yes. After a brief surge, 91.2% to 97.7% of men reached 50 ng/dL or less by day 29 in the label trials (Trelstar label).
Can triptorelin be used after a steroid cycle to restart testosterone?
We found no study of that. The depot lowers testosterone, and the evidence for GnRH-based restart is for pulsed gonadorelin in men with a missing signal, not a steady agonist (Trelstar label; Matsumoto et al., 1991).
What are the side effects of triptorelin?
Hot flushes (58.6% of men on 3.75 mg), bone pain, impotence, headache and injection-site reactions, with label warnings for tumor flare, metabolic changes, heart attack and stroke, convulsions, severe skin reactions, QT prolongation and fetal harm (Trelstar label).
Does triptorelin cause weight gain?
In 58 men, androgen deprivation with triptorelin or surgery raised fat mass, abdominal fat, cholesterol and insulin resistance and lowered lean body mass within 12 to 24 weeks (Østergren et al., 2019).
How long does a triptorelin injection last?
The approved depots are given every 4 weeks (3.75 mg), 12 weeks (11.25 mg) or 24 weeks (22.5 mg), by a nurse or doctor into a muscle (Trelstar label; Mayo Clinic).
Is triptorelin FDA-approved?
What is the difference between triptorelin and gonadorelin?
Gonadorelin is the natural GnRH, which works in pulses; triptorelin is a stronger copy given as a steady depot that switches the system off. See what the research shows on gonadorelin (Trelstar label; Matsumoto et al., 1991).
Is triptorelin used for endometriosis?
In the U.K., yes: Decapeptyl SR and Gonapeptyl Depot list it. It is not FDA-approved for it. In small trials it was as effective as danazol and dienogest, and a 2023 Cochrane review rates the evidence very low to low (Decapeptyl SR 3 mg; Cirkel et al., 1995; Veth et al., 2023).
Is triptorelin banned in sports?
For male athletes, yes. The 2026 WADA list names GnRH agonist analogues, including triptorelin, prohibited at all times (WADA, 2026).
Are there triptorelin clinical trials?
Yes. ClinicalTrials.gov’s intervention search for triptorelin and its brand names returns 59 recruiting, not-yet-recruiting or enrolling-by-invitation studies and 20 active, not recruiting studies (November 16, 2026). We list the 22 recruiting trials that test triptorelin itself, in IVF, breast cancer and ovary protection, early puberty, endometriosis and prostate cancer, and 2 more in progress. The rest name it as one of several hormone drugs or as part of a protocol (recruiting list; in-progress list; search).
Sources
- Teillac P, et al. Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer. Horm Res. 2004;62(5):252-8. PubMed 15499224
- Bolton EM, et al. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review. BJU Int. 2018;122(3):371-383. PubMed 29438592
- Østergren PB, et al. Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study. BJU Int. 2019;123(4):602-611. PubMed 30388320
- Durand A, et al. Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation . Horm Res Paediatr. 2017;87(4):224-232. PubMed 28334719
- Yu X, et al. A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty. Adv Ther. 2024;41(12):4537-4556. PubMed 39412628
- Carel JC, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab. 1999;84(6):1973-8. PubMed 10372696
- Firwana M, et al. A systematic review supporting the Endocrine Society clinical practice guidelines on central precocious puberty. J Clin Endocrinol Metab. 2026;111(8):2145-2153. PubMed 42287191
- Luo X, et al. Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: A systematic review and meta-analysis. Clin Endocrinol (Oxf). 2021;94(5):786-796. PubMed 33387371
- Cirkel U, et al. A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. Eur J Obstet Gynecol Reprod Biol. 1995;59(1):61-9. PubMed 7781864
- Cosson M, et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril. 2002;77(4):684-92. PubMed 11937116
- Donnez J, et al. Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis. Fertil Steril. 2004;81(2):297-304. PubMed 14967363
- Veth VB, et al. Gonadotropin-releasing hormone analogues for endometriosis. Cochrane Database Syst Rev. 2023;6(6):CD014788. PubMed 37341141
- Puscasiu L, et al. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev. 2025;4(4):CD000547. PubMed 40183418
- Perrone F, et al. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. Eur J Cancer. 2019;118:178-186. PubMed 31164265
- Pagani O, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107-18. PubMed 24881463
- Lambertini M, et al. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. JAMA. 2015;314(24):2632-40. PubMed 26720025
- Lambertini M, et al. Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients. J Natl Cancer Inst. 2022;114(3):400-408. PubMed 34850043
- Lambertini M, et al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J Clin Oncol. 2018;36(19):1981-1990. PubMed 29718793
- Demeestere I, et al. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. J Clin Oncol. 2016;34(22):2568-74. PubMed 27217453
- Siristatidis CS, et al. Gonadotropin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev. 2025;1(1):CD006919. PubMed 39783453
- Youssef MA, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014;2014(10):CD008046. PubMed 25358904
- Rösler A, et al. Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med. 1998;338(7):416-22. PubMed 9459644
- Thibaut F, et al. Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr Scand. 1993;87(6):445-50. PubMed 8356897
- Briken P, et al. [Failure of a study in forensic psychiatric hospitals : Clinical trial to investigate the additive effect of triptorelin on the efficacy of psychotherapy]. Nervenarzt. 2017;88(5):480-485. PubMed 28289788
- Taylor J, et al. Interventions to suppress puberty in adolescents experiencing gender dysphoria or incongruence: a systematic review. Arch Dis Child. 2024;109(Suppl 2):s33-s47. PubMed 38594047
- Miroshnychenko A, et al. Puberty blockers for gender dysphoria in youth: A systematic review and meta-analysis. Arch Dis Child. 2025;110(6):429-436. PubMed 39855724
- Nomani H, et al. Anti-Androgen Drugs in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Curr Med Chem. 2020;27(40):6825-6836. PubMed 31814547
- Matsumoto AM, et al. The physiological significance of pulsatile LHRH secretion in man: gonadotrophin responses to physiological doses of pulsatile versus continuous LHRH administration. Int J Androl. 1991;14(1):23-32. PubMed 1901051
- U.S. Food and Drug Administration. Trelstar (triptorelin) prescribing information, label effective June 30, 2026. DailyMed
- U.S. Food and Drug Administration. Triptodur (triptorelin) prescribing information, label effective September 14, 2025. DailyMed
- U.S. Food and Drug Administration. Drugs@FDA: Trelstar 3.75 mg (NDA020715), 11.25 mg (NDA021288) and 22.5 mg (NDA022437), and Triptodur (NDA208956), November 16, 2026. NDA020715 NDA021288 NDA022437 NDA208956
- U.S. Food and Drug Administration. openFDA drug listings (NDC): the Trelstar and Triptodur kits and 10 further listings that name triptorelin, November 16, 2026. openFDA NDC
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding (content current as of April 22, 2026; triptorelin not named). FDA page
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories, updated May 14, 2026 (triptorelin not named). FDA document
- Electronic Medicines Compendium (U.K.). Summaries of product characteristics: Decapeptyl SR 3 mg (updated June 9, 2026), Decapeptyl SR 11.25 mg, Gonapeptyl Depot 3.75 mg (updated October 20, 2025) and Salvacyl 11.25 mg (updated June 27, 2025). Decapeptyl SR 3 mg Decapeptyl SR 11.25 mg Gonapeptyl Depot Salvacyl
- Mayo Clinic. Triptorelin (intramuscular route): drug information from Merative Micromedex, portions last updated November 1, 2026. Mayo Clinic page
- MedlinePlus. Triptorelin injection: drug information, January 15, 2026. MedlinePlus page
- UniProt. Progonadoliberin-1 (P01148): gonadoliberin-1 is residues 24 to 33, with glycine at position 6 of the peptide. UniProt
- ClinicalTrials.gov. Intervention search for triptorelin, Trelstar, Triptodur and Decapeptyl, November 16, 2026. Search
- World Anti-Doping Agency. 2026 Prohibited List, section S2.2.1 (GnRH, gonadorelin and its agonist analogues, including triptorelin, in males); text checked in a national copy of the 2026 list because the WADA file would not download. WADA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- National Library of Medicine. PubChem compound record: Triptorelin (CID 25074470). PubChem
Last reviewed Nov 16, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.